{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T06:38:07Z","timestamp":1777617487882,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,23]],"date-time":"2023-05-23T00:00:00Z","timestamp":1684800000000},"content-version":"vor","delay-in-days":387,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.jtct.2022.02.014","type":"journal-article","created":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T09:50:30Z","timestamp":1645350630000},"page":"242-247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis"],"prefix":"10.1016","volume":"28","author":[{"given":"Parameswaran","family":"Hari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9117-8696","authenticated-orcid":false,"given":"Saurabh","family":"Chhabra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.02.014_bib0001","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Cancer Stat Facts: Myeloma. National Cancer Institute. Available at: https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed Oct 19, 2021."},{"key":"10.1016\/j.jtct.2022.02.014_bib0002","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41408-018-0155-7","article-title":"Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma - an IMWG Research Project","volume":"8","author":"Usmani","year":"2018","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.02.014_bib0003","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.02.014_bib0004","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.bbmt.2015.03.002","article-title":"Hematopoietic stem cell transplantation for multiple myeloma: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Shah","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0005","unstructured":"Phelan R, Arora M, Chen M. Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides, 2020. Available at: https:\/\/www.ecosia.org\/search\/ q\u00a0=\u00a0Current+ use+ and+ outcome+ of+ hematopoietic+ stem+ cell+ transplantation% 3A+ CIBMTR+ summary+ slides% 2C+ 2020&addon\u00a0=\u00a0safari&addonversion. Accessed Oct 15, 2021."},{"key":"10.1016\/j.jtct.2022.02.014_bib0006","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1038\/leu.2017.185","article-title":"Trends in pre- and post-transplant therapies with first autologous hematopoietic cell transplantation among patients with multiple myeloma in the United States, 2004\u20132014","volume":"31","author":"D'Souza","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.02.014_bib0007","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.bbmt.2019.01.007","article-title":"Induction therapy with bortezomib and dexamethasone and conditioning with high-dose melphalan and bortezomib followed by autologous stem cell transplantation for immunoglobulin light chain amyloidosis: long-term follow-up analysis","volume":"25","author":"Gupta","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0008","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/bmt.2012.170","article-title":"Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis","volume":"48","author":"Gertz","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0009","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2016.229","article-title":"Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis","volume":"31","author":"Landau","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.02.014_bib0010","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.bbmt.2018.06.018","article-title":"Modified high-dose melphalan and autologous stem cell transplantation for immunoglobulin light chain amyloidosis","volume":"24","author":"Nguyen","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0011","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood.V99.3.731","volume":"99","author":"Moreau","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.014_bib0012","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","article-title":"High-dose intravenous melphalan: a review","volume":"13","author":"Samuels","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.02.014_bib0013","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0014","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1053\/j.seminoncol.2003.11.040","article-title":"The effect of oral mucositis on morbidity and mortality in bone marrow transplant","volume":"30","author":"Gabriel","year":"2003","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtct.2022.02.014_bib0015","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clml.2014.02.001","article-title":"The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation","volume":"14","author":"Fleming","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2022.02.014_bib0016","unstructured":"Acrotech Biopharma Inc. EVOMELA (melphalan) for injection [package insert] US Food and Drug Administration. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/207155s001lbl.pdf. Accessed Aug 30, 2021."},{"key":"10.1016\/j.jtct.2022.02.014_bib0017","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1038\/bmt.2014.120","article-title":"Phase IIa cross-over study of propylene glycol-free melphalan (LGD-353) and Alkeran in multiple myeloma autologous transplantation","volume":"49","author":"Aljitawi","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0018","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.bbmt.2015.08.026","article-title":"A phase IIb, multicenter, open-label, safety, and efficacy study of high-dose, propylene glycol-free melphalan hydrochloride for injection (EVOMELA) for myeloablative conditioning in multiple myeloma patients undergoing autologous transplantation","volume":"21","author":"Hari","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.jtct.2022.02.014_bib0019","doi-asserted-by":"crossref","first-page":"3446","DOI":"10.1182\/blood-2018-99-119730","article-title":"Safety and efficacy of Evomela in myeloma autotransplants","volume":"132","author":"Amelsberg","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.014_bib0020","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.1182\/blood.V99.12.4276","article-title":"Autologous stem cell transplantation for primary systemic amyloidosis","volume":"99","author":"Comenzo","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.014_bib0021","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s41409-018-0302-6","article-title":"Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma","volume":"54","author":"Miller","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-141105","article-title":"Comparison of patient outcomes with two different formulations of melphalan as conditioning chemotherapy for autologous stem cell transplantation in multiple myeloma","volume":"136","author":"Yucebay","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.014_bib0023","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1038\/s41409-018-0178-5","article-title":"Use of propylene glycol-free melphalan conditioning in light-chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is well tolerated and effective","volume":"53","author":"Badar","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0024","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1038\/s41409-018-0388-x","article-title":"Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation","volume":"54","author":"Sidiqi","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0025","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1016\/j.bbmt.2020.08.030","article-title":"Propylene glycol-free melphalan versus PG-melphalan as conditioning for autologous hematopoietic cell transplantation for myeloma","volume":"26","author":"Monahan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0026","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/sj.bmt.1703015","article-title":"Engraftment syndrome following hematopoietic stem cell transplantation","volume":"27","author":"Spitzer","year":"2001","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2022.02.014_bib0027","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/j.bbmt.2018.12.365","article-title":"Toxicity analysis of propylene glycol-free melphalan (Evomela) compared to propylene glycol-based melphalan hydrochloride in autologous hematopoietic cell transplantation for multiple myeloma","volume":"25","author":"DeRespiris","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0028","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1182\/blood-2019-132114","article-title":"Evomela significantly increases the risk of engraftment syndrome in patients with multiple myeloma treated with autologous stem cell transplantation","volume":"134","author":"McKenna","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.02.014_bib0029","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/j.bbmt.2018.04.028","article-title":"Pharmacokinetics of high-dose propylene glycol\u2013free melphalan in multiple myeloma patients undergoing autologous hematopoietic cell transplantation","volume":"24","author":"Dhakal","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0030","first-page":"3296","article-title":"Pharmacokinetics and toxicities after Evomela (propylene glycol free melphalan) with autologous hematopoietic stem cell transplant (AHCT) for multiple myeloma and AL amyloidosis","volume":"130","author":"Shah","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2022.02.014_bib0031","doi-asserted-by":"crossref","first-page":"S129","DOI":"10.1016\/j.bbmt.2017.12.072","article-title":"Feasibility and toxicity of pharmacokinetic (PK)-directed dosing of Evomela (propylene glycol free melphalan, PGF-MEL) for multiple myeloma (MM) and AL amyloidosis (AL) patients undergoing autologous hematopoietic stem cell transplant (AHCT)","volume":"24","author":"Shah","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2022.02.014_bib0032","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.bbmt.2019.12.707","article-title":"Successful personalization of propylene glycol free Melphalan (PGF-MEL) for multiple myeloma (MM) and AL amyloidosis (AL) patients undergoing autologous hematopoietic stem cell transplant (AAHCT) using pharmacokinetic (PK)-directed dosing","volume":"26","author":"Shah","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0033","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/sj.bmt.1701763","article-title":"Melphalan 220 mg\/m2 followed by peripheral blood stem cell transplantation in 27 patients with advanced multiple myeloma","volume":"23","author":"Moreau","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0034","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1038\/bmt.2014.186","article-title":"Not too little, not too much-just right! (Better ways to give high dose melphalan)","volume":"49","author":"Shaw","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.02.014_bib0035","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3324\/haematol.2017.181339","article-title":"Melphalan 140 mg\/m2 or 200 mg\/m2 for autologous transplantation in myeloma: results from the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study. A report by the EBMT Chronic Malignancies Working Party","volume":"103","author":"Auner","year":"2018","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2022.02.014_bib0036","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1177\/1078155218804042","article-title":"Evaluating the adverse effects of melphalan formulations","volume":"25","author":"Xiang","year":"2019","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jtct.2022.02.014_bib0037","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1177\/1078155220987623","article-title":"Evaluating the incidence of engraftment syndrome with different melphalan formulations in adult multiple myeloma and immunoglobulin light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation","volume":"28","author":"Kowalski","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"10.1016\/j.jtct.2022.02.014_bib0038","unstructured":"Maung K, Chao N, Corbet K, Engemann AM, Gasparetto C, Horwitz M, et al. Retrospective study of safety and toxicity profile comparison for propylene glycol-free melphalan (Evomela) and propylene glycol-solubilized melphalan."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672200094X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266663672200094X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:01:46Z","timestamp":1763002906000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266663672200094X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S266663672200094X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.02.014","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Review of Propylene Glycol-free Melphalan Conditioning for Hematopoietic Cell Transplantation for Multiple Myeloma and Light Chain Amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.02.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}